More Potential
More Potential
Search
Corporate Compliance Program
Our E&C Program conforms with the principles and recommendations published in guides from various Federal agencies and industry related organizations
Management Rotation | Academic Programs
Management Rotation Program
We’re All In
We’re All In
Our People, Our Culture
Our People, Our Culture
A Planned Safety Net for Patients in Need
A Planned Safety Net for Patients in Need
Swine
Swine
Partnering with Boehringer Ingelheim
Information on partnering with Boehringer Ingelheim including how the company enables new science, partnering interests and key facts on the R&D pipeline.
Metabolic Diseases
CardioMetabolic Disease Research
Life Forward
In everything we do we can shape and influence the future for the better: Learn more about “Life forward” and how our innovations improve lives.
Oncology & Cancer Immunology
We are looking for new early-science collaborations and invite you to join our expanding community of innovation partners in oncology.
Topline results from Boehringer's Phase III IPF Study
Press release announcing topline results of Boehringer Ingelheim's Phase III FIBRONEER-IPF study in indiopathic pulmonary fibrosis
Citizen Petition
Citizen Petition
Boehringer Ingelheim Announces the Launch of Centragard™ (eprinomectin and praziquantel transdermal solution), Innovative Internal Parasite Protection For Cats
Boehringer Ingelheim Announces the Launch of Centragard™ (eprinomectin and praziquantel transdermal solution), Innovative Internal Parasite Protection For Cats
More Green | Sustainable Development
Our MORE GREEN pillar encompasses initiatives that consider many different aspects: adopting measures to avoid water and air pollution, & much more.
Rising Star Leads with Determination | Boehringer Ingelheim US
Click to find out more on our partnership with the HBA, where we honor a BI colleague as a “Rising Star” to support the advancement of women in health care.
Boehringer Ingelheim refocuses Gly-T1 inhibition brain research on schizophrenia
Boehringer Ingelheim refocuses Gly-T1 inhibition brain research on schizophrenia
Community Guidelines
We welcome your comments and posts and look forward to a dialogue about science & health and our commitment to bring More Health to people around the world.
Partnering Culture
BI's long-term research and investment focus means we can work together to realize their ideas by fully committing to lasting relationships.
Boehringer Ingelheim Office Hours Video 2023
Video providing an overview of Boehringer Ingelheim’s Office Hours program and how its mentoring and access to expertise can help early-stage companies advance their science.
AbeXXa Biologics – Re-Imagining Cancer Immunotherapy for the Many
AbeXXa Biologics – Re-Imagining Cancer Immunotherapy for the Many
Fostering Science | Boehringer Ingelheim US
Find out how creating breakthrough medicines to change patients’ lives starts with a commitment to identify the challenges of the future & emerging science.
About Us
Click here to discover more about Boehringer Ingelheim and our headquarters and largest U.S subsidiary in Connecticut.
Poultry
Poultry
Gastrointestinal Cancers
Gastrointestinal Cancers